Skip to content

Microbot Medical MBOT Inducement Transaction Cost

Inducement Transaction Cost at other companies

XTI Aerospace, Inc. logo
XTI Aerospace, Inc.XTIA
$6.7M
KEE
Keel Infrastructure Corp. Common StockKEEL
$975K
NMP
Nuveen Prem Inc Muni FundNMP
$5.46M+300%
KEE
Keel Infrastructure Corp. Common StockKEEL
$975K
SVC
Stellar V Capital Corp. Class A Ordinary SharesSVCC
$8.78M
SelectQuote logo
SelectQuoteSLQT
$631K-89.1%

Other financials

Income statement

See full
Revenue$105.0K
Gross profit$2.0K
Operating income-$4.3M-43.0%
Net income-$3.7M-41.1%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$3.7M+13.7%
Total debt$898.0K+551%
Total equity$74.1M+156%
Total assets$78.1M+153%

Cash flow

See full
Operating cash flow-$5.1M-75.8%
CapEx$108.0K+731%
Free cash flow-$5.2M-78.8%

Valuation

See full
Market cap$128.28M+36.1%
Enterprise value$125.53M+39.0%
P/S674.3×

Profitability

See full
Operating margin25,292.9%
Net margin-3,669.9%
FCF margin-852.8%

Returns & leverage

See full
Return on equity-27.6%-10.2pp
Debt / equity0.0×
Current ratio22.6×+6.4×

Where this comes from

Reported directly by Microbot Medical in its filing.

Tagged under the XBRL concept MBOT:InducementTransactionCost.

The official record: Microbot Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Microbot Medical's inducement transaction cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Microbot Medical's inducement transaction cost?
Microbot Medical (MBOT) reported inducement transaction cost of $2.47K in Q1 2026.
What does inducement transaction cost mean?
Costs incurred by the company specifically to incentivize parties to enter into or modify financial transactions, such as debt restructuring or equity issuance. These expenses are often non-recurring and reflect the premium paid to secure necessary capital or strategic partnerships. Analyzing these costs helps in understanding the efficiency of the company's financing activities.